Abstract
Dyskinesia in Parkinson’s disease: an update on new neuroimaging methods and treatment possibilities
Levodopa-induced dyskinesia (LID) represents a severe adverse effect of long-term treatment of Parkinson’s disease with levodopa. Neuroimaging studies have contributed to our understanding of LID and may help to identify patients at risk of developing LID. Amantadine can be used for the treatment of LID, and novel drugs are under development. Deep brain stimulation of the subthalamic nucleus and globus pallidus internus alleviates LID, the former indirectly by reducing levodopa intake, the latter through direct effects. Repetitive transcranial magnetic stimulation has been shown to transiently improve LID.
Levodopa-induced dyskinesia (LID) represents a severe adverse effect of long-term treatment of Parkinson’s disease with levodopa. Neuroimaging studies have contributed to our understanding of LID and may help to identify patients at risk of developing LID. Amantadine can be used for the treatment of LID, and novel drugs are under development. Deep brain stimulation of the subthalamic nucleus and globus pallidus internus alleviates LID, the former indirectly by reducing levodopa intake, the latter through direct effects. Repetitive transcranial magnetic stimulation has been shown to transiently improve LID.
| Originalsprog | Dansk |
|---|---|
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 179 |
| Udgave nummer | 9 |
| Sider (fra-til) | 2-6 |
| Antal sider | 5 |
| ISSN | 0041-5782 |
| Status | Udgivet - 6 mar. 2017 |